Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL-Reference-Cited by-同舟云学术

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Published:2017-05-11 Issue:19 Volume:129 Page:2612-2615
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Barr Paul M.¹^ORCID,Brown Jennifer R.²,Hillmen Peter³,O'Brien Susan⁴,Barrientos Jacqueline C.⁵,Reddy Nishitha M.⁶,Coutre Steven⁷,Mulligan Stephen P.⁸,Jaeger Ulrich⁹,Furman Richard R.¹⁰,Cymbalista Florence¹¹,Montillo Marco¹²,Dearden Claire¹³,Robak Tadeusz¹⁴,Moreno Carol¹⁵,Pagel John M.¹⁶,Burger Jan A.⁴,Suzuki Samuel¹⁷,Sukbuntherng Juthamas¹⁷,Cole George¹⁷,James Danelle F.¹⁷,Byrd John C.¹⁸

Affiliation:

1. Wilmot Cancer Institute, University of Rochester, Rochester, NY;

2. Dana-Farber Cancer Institute, Boston, MA;

3. The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom;

4. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;

5. Hofstra Northwell School of Medicine, Hempstead, NY;

6. Vanderbilt-Ingram Cancer Center, Nashville, TN;

7. Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA;

8. Royal North Shore Hospital, Sydney, NSW, Australia;

9. Division of Hematology, Department of Medicine I, Medical University of Vienna, Vienna, Austria;

10. Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY;

11. Hôpital Avicenne, Paris, France;

12. Niguarda Ca’ Granda Hospital, Milan, Italy;

13. Royal Marsden Hospital, London, United Kingdom;

14. Department of Hematology, Medical University of Lodz, Lodz, Poland;

15. Hospital de la Santa Creu Sant Pau, Barcelona, Spain;

16. Swedish Cancer Institute, Seattle, WA;

17. Pharmacyclics LLC, AbbVie, Sunnyvale, CA;

18. The Ohio State University Medical Center, The Ohio State University, Columbus, OH

Abstract

Key Points Higher ibrutinib DI is associated with improved PFS, independent of del17p or TP53 mutation. Ibrutinib hold for >1 week, often needed to manage adverse events, is associated with increased PFS events.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/19/2612/1400104/blood737346.pdf

Reference15 articles.

1. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia;Rai;N Engl J Med,2000

2. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions;Goede;N Engl J Med,2014

3. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

4. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia;Byrd;Blood,2016

5. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia;Byrd;N Engl J Med,2014

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program;The Oncologist;2024-09-14

2. Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation;Blood Neoplasia;2024-09

3. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia;Expert Review of Hematology;2024-08-21

4. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

5. Treatment adherence and adverse event management in chronic lymphocytic leukemia: challenges and strategies for the future;Expert Review of Clinical Pharmacology;2024-04-25